André Moser

André Moser

Auto-generated profile, based on publicly available information

André Moser

Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
AMAndré Moser
André Moser
ASAndreas E. Stuck
Andreas E. Stuck
RSRebecca A. Silliman
Rebecca A. Silliman
PGPatricia A. Ganz
Patricia A. Ganz
KCKerri M. Clough-Gorr
Kerri M. Clough-Gorr

1 May 2012 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SSStefan Stortecky
Stefan Stortecky
ASAndreas W. Schoenenberger
Andreas W. Schoenenberger
AMAndré Moser
André Moser
BKBindu Kalesan
Bindu Kalesan
PJPeter Jüni
Peter Jüni
PWPeter Wenaweser
Peter Wenaweser

24 September 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ASAndreas W. Schoenenberger
Andreas W. Schoenenberger
SSStefan Stortecky
Stefan Stortecky
SNStephanie Neumann
Stephanie Neumann
AMAndré Moser
André Moser
PJPeter Jüni
Peter Jüni
PWPeter Wenaweser
Peter Wenaweser
This study aimed to assess functional course in elderly patients undergoing transcatheter aortic valve implantation (TAVI) and to find predictors of functional decline. In this prospective cohort, functional course was assessed in patients ≥70 years using basic activities of daily living (BADL) before and 6 months after TAVI. Baseline EuroSCORE, STS score, and a frailty index (based on assessment of cognition, mobility, nutrition, instrumental and basic activities of daily living) were evaluated to predict functional decline (deterioration in BADL) using logistic regression models. Functional decline was observed in 22 (20.8%) of 106 surviving patients. EuroSCORE (OR per 10% increase 1.18, 95% CI: 0.83–1.68, P = 0.35) and STS score (OR per 5% increase 1.64, 95% CI: 0.87–3.09, P = 0.13) weakly predicted functional decline. In contrast, the frailty index strongly predicted functional decline in univariable (OR per 1 point increase 1.57, 95% CI: 1.20–2.05, P = 0.001) and bivariable analyses (OR: 1.56, 95% CI: 1.20–2.04, P = 0.001 controlled for EuroSCORE; OR: 1.53, 95% CI: 1.17–2.02, P = 0.002 controlled for STS score). Overall predictive performance was best for the frailty index [Nagelkerke's R2 (NR2) 0.135] and low for the EuroSCORE (NR2 0.015) and STS score (NR2 0.034). In univariable analyses, all components of the frailty index contributed to the prediction of functional decline. Over a 6-month period, functional status worsened only in a minority of patients surviving TAVI. The frailty index, but not established risk scores, was predictive of functional decline. Refinement of this index might help to identify patients who potentially benefit from additional geriatric interventions after TAVI.

28 January 2017 in AIDS
Verified
Journal Article
Open access
AGAysel Gueler
Aysel Gueler
AMAndré Moser
André Moser
ACAlexandra Calmy
Alexandra Calmy
HGHuldrych Günthard
Huldrych Günthard
EBEnos Bernasconi
Enos Bernasconi
MEMatthias Egger
Matthias Egger
Objectives: To estimate life expectancy over 25 years in HIV-positive people and to compare their life expectancy with recent estimates for the general population, by education. Methods: Patients aged 20 years or older enrolled in the Swiss HIV Cohort Study 1988–2013 were eligible. Patients alive in 2001 were matched to up to 100 Swiss residents, by sex, year of birth, and education. Life expectancy at age 20 was estimated for monotherapy (1988–1991), dual therapy (1992–1995), early combination antiretroviral therapy (cART, 1996–1998), later cART (1999–2005) and recent cART (2006–2013) eras. Parametric survival regression was used to model life expectancy. Results: In all, 16 532 HIV-positive patients and 927 583 residents were included. Life expectancy at age 20 of HIV-positive individuals increased from 11.8 years [95% confidence interval (CI) 11.2–12.5] in the monotherapy era to 54.9 years (95% CI 51.2–59.6) in the most recent cART era. Differences in life expectancy across educational levels emerged with cART. In the most recent cART period, life expectancy at age 20 years was 52.7 years (95% CI 46.4–60.1) with compulsory education, compared to 60.0 years (95% CI 53.4–67.8) with higher education. Estimates for the general population were 61.5 and 65.6 years, respectively. Male sex, smoking, injection drug use, and low CD4+ cell counts at enrolment were also independently associated with mortality. Conclusion: In Switzerland, educational inequalities in life expectancy were larger among HIV-infected persons than in the general population. Highly educated HIV-positive people have an estimated life expectancy similar to Swiss residents with compulsory education. Earlier start of cART and effective smoking-cessation programs could improve HIV-positive life expectancy further and reduce inequalities.

6 January 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
VWViktor von Wyl
Viktor von Wyl
MHMarc Höglinger
Marc Höglinger
CSChloé Sieber
Chloé Sieber
MKMarco Kaufmann
Marco Kaufmann
AMAndré Moser
André Moser
MPMilo Alan Puhan
Milo Alan Puhan
Background: Digital proximity tracing apps have been released to mitigate the transmission of SARS-CoV-2, the virus known to cause COVID-19. However, it remains unclear how the acceptance and uptake of these apps can be improved. Objective: This study aimed to investigate the coverage of the SwissCovid app and the reasons for its nonuse in Switzerland during a period of increasing incidence of COVID-19 cases. Methods: We collected data between September 28 and October 8, 2020, via a nationwide online panel survey (COVID-19 Social Monitor, N=1511). We examined sociodemographic and behavioral factors associated with app use by using multivariable logistic regression, whereas reasons for app nonuse were analyzed descriptively. Results: Overall, 46.5% (703/1511) of the survey participants reported they used the SwissCovid app, which was an increase from 43.9% (662/1508) reported in the previous study wave conducted in July 2020. A higher monthly household income (ie, income >CHF 10,000 or >US $11,000 vs income ≤CHF 6000 or <US $6600 [reference]: odds ratio [OR] 1.92, 95% CI 1.40-2.64), more frequent internet use (ie, daily [reference] vs less than weekly: OR 0.37, 95% CI 0.16-0.85), better adherence to recommendations for wearing masks (ie, always or most of the time [reference] vs rarely or never: OR 0.28, 95% CI 0.15-0.52), and nonsmoker status (OR 1.32, 95% CI 1.01-1.71) were associated with an increased likelihood for app uptake. Citizenship status (ie, non-Swiss citizenship vs. Swiss [reference]: OR 0.61, 95% CI 0.43-0.87), and language region (French vs Swiss German [reference]: OR 0.61, 95% CI 0.46-0.80) were associated with a lower likelihood for app uptake. Further analysis in a randomly selected subsample (n=712) with more detailed information showed that higher levels of trust in government and health authorities were also associated with a higher likelihood for app uptake (ie, high vs low [reference] trust: OR 3.13, 95% CI 1.58-6.22). The most frequent reasons for app nonuse were lack of perceived benefit of using the app (297/808, 36.8%), followed by the lack of a compatible phone (184/808, 22.8%), and privacy concerns (181/808, 22.4%). Conclusions: Eliminating technical hurdles and communicating the benefits of digital proximity tracing apps are crucial to promote further uptake and adherence of such apps and, ultimately, enhance their effectiveness to aid pandemic mitigation strategies.

1 February 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ASAndreas W. Schoenenberger
Andreas W. Schoenenberger
AMAndré Moser
André Moser
DBDominic Bertschi
Dominic Bertschi
PWPeter Wenaweser
Peter Wenaweser
SWStephan Windecker
Stephan Windecker
SSStefan Stortecky
Stefan Stortecky